{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-22-000137","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.942704+00:00","generated_at":"2026-06-22T21:00:07.199085+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q3 revenue $156.4M, GAAP EPS $(0.43); cuts FY22 guidance; acquires Gateway Genomics for $67.5M","bullets":["Revenue $156.4M (-2% YoY); GAAP EPS $(0.43), adjusted EPS $(0.19).","GeneSight volumes +34% YoY; hereditary cancer volumes +4% YoY; total testing volumes +12% ex-divestitures.","Acquired Gateway Genomics for $67.5M cash plus up to $32.5M earnout; Gateway expected to be accretive in 2024.","FY2022 revenue guidance cut to $668-672M (prev. $670-700M); adjusted EPS guided to $(0.35)-$(0.30).","Quarter-end cash $259.2M, no debt; operating cash flow -$2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-22-000137","json":"https://secwatch.observer/filing/0000899923-22-000137.json","markdown":"https://secwatch.observer/filing/0000899923-22-000137.md","text":"https://secwatch.observer/filing/0000899923-22-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/0000899923-22-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/mygn-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:00:07.199085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97bef3c14a69653267eb238f4bf15357a52cbd33","claim":"MYRIAD GENETICS INC reported the three months ended September 30, 2022 results: revenue $156.4 million, EPS $(0.43).","evidence_excerpt":"Myriad Genetics Reports Third Quarter Financial Results Highlights: • Revenue of $156.4 million for the quarter ended September 30, 2022. ▪ Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates 1 ($5.3 million). ▪ Third quarter testing volumes, excluding divested businesses, grew 12% year-over-year. Hereditary cancer testing volume continued to improve in 2022 and grew 4% year-over-year in the third quarter. GeneSight volumes grew 34% over third quarter of 2021. ▪ We believe that the underlying pricing of Myriad testing products remains stable, notwithstanding that average selling price overall was negatively impacted by currency translations, change of estimates and a non-recurring milestone payment in the third quarter. • Diluted GAAP earnings per share (EPS) were $(0.43) and adjusted EPS were $(0.19) in the third quarter of 2022 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/0000899923-22-000137-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$156.4 million"},{"label":"EPS","value":"$(0.43)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}